Prolonged prophylaxis in orthopedic surgery: Insights from the United States

被引:15
作者
Anderson, FA [1 ]
White, K [1 ]
机构
[1] Univ Massachusetts, Dept Surg, Ctr Outcomes Res, Sch Med, Worcester, MA 01605 USA
关键词
orthopedic surgeons; total hip arthroplasty; total knee arthroplasty; thromboprophylaxis; prolonged prophylaxis;
D O I
10.1055/s-2002-34075
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The U.S. Hip and Knee Registry is a voluntary national registry of outcome data for hip and knee surgery. In total, 469 orthopedic surgeons from 325 hospitals reported data on 7677 patients who underwent total hip arthroplasty (THA) and 11,461 patients who underwent total knee arthroplasty (TKA). Data on patients enrolled between 1996 and 2000 indicate that 40% of THA patients and 42% of TKA patients received prophylaxis for a period of 8 to 21 days, including the in-hospital period. Prolonged prophylaxis for more than 21 days was used in 49% of THA patients and 44% of TKA patients. Moreover, year on year, data indicate that the percentage of patients who receive prophylaxis for longer than 21 days is gradually increasing. In 2000, 53% of THA patients and 47% of TKA patients received prophylaxis for longer than 21 days.
引用
收藏
页码:43 / 46
页数:4
相关论文
共 9 条
[1]   Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement [J].
Bergqvist, D ;
Benoni, G ;
Bjorgell, O ;
Fredin, H ;
Hedlundh, U ;
Nicolas, S ;
Nilsson, P ;
Nylander, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :696-700
[2]  
Cohen AT, 2000, HAEMOSTASIS, V30, P88
[3]   Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement [J].
Comp, PC ;
Spiro, TE ;
Friedman, RJ ;
Whitsett, TL ;
Johnson, GJ ;
Gardiner, GA ;
Landon, GC ;
Jové, M .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2001, 83A (03) :336-345
[4]  
Dahl OE, 1997, THROMB HAEMOSTASIS, V77, P26
[5]   Prevention of venous thromboembolism [J].
Geerts, WH ;
Heit, JA ;
Clagett, GP ;
Pineo, GF ;
Colwell, CW ;
Anderson, FA ;
Wheeler, HB .
CHEST, 2001, 119 (01) :132S-175S
[6]  
HUBER O, 1992, ARCH SURG-CHICAGO, V127, P310
[7]  
Hull RD, 1999, THROMB HAEMOSTASIS, P6
[8]   Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish prolonged prophylaxis (DaPP) study [J].
Lassen, MR ;
Borris, LC ;
Anderson, BS ;
Jensen, HP ;
Bro, HPS ;
Andersen, G ;
Petersen, AO ;
Siem, P ;
Horlyck, E ;
Jensen, BV ;
Thomsen, PB ;
Hansen, BR ;
Erin-Madsen, J ;
Moller, JC ;
Rotwitt, L ;
Christensen, F ;
Nielsen, JB ;
Jorgensen, PS ;
Paaske, B ;
Torholm, C ;
Hvidt, P ;
Jensen, NK ;
Nielsen, AB ;
Appelquist, E ;
Hansen, OG ;
Mortensen, D ;
Tjalve, E .
THROMBOSIS RESEARCH, 1998, 89 (06) :281-287
[9]   Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo [J].
Planes, A ;
Vochelle, N ;
Darmon, JY ;
Fagola, M ;
Bellaud, M ;
Huet, Y .
LANCET, 1996, 348 (9022) :224-228